Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
Status:
Active, not recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of RAD001
(everolimus) and Femara (letrozole) can help to control recurrent or progressive endometrial
cancer. The safety of this drug combination will also be studied.